Modulation of the Fecal Bile Acid Profile by Gut Microbiota in Cirrhosis
Genta Kakiyama,William M. Pandak,Patrick M. Gillevet,Phillip B. Hylemon,Douglas M. Heuman,Kalyani Daita,Hajime Takei,Akina Muto,Hiroshi Nittono,Jason M. Ridlon,Melanie B. White,Nicole A. Noble,Pamela Monteith,Michael Fuchs,Leroy R. Thacker,Masoumeh Sikaroodi,Jasmohan S. Bajaj +16 more
Reads0
Chats0
TLDR
Cirrhosis, especially advanced disease, is associated with a decreased conversion of primary to secondary fecal BAs, which is linked to abundance of key gut microbiome taxa.About:
This article is published in Journal of Hepatology.The article was published on 2013-05-01 and is currently open access. It has received 572 citations till now. The article focuses on the topics: Bile acid & Deoxycholic acid.read more
Citations
More filters
Journal ArticleDOI
Introduction to the human gut microbiota
Elizabeth Thursby,Nathalie Juge +1 more
TL;DR: This review summarises the current understanding of the development and composition of the human GI microbiota, and its impact on gut integrity and host health, underlying the need for mechanistic studies focusing on host–microbe interactions.
Journal ArticleDOI
Bile Acids and the Gut Microbiome
TL;DR: The host and microbiome appear to regulate bile acid pool size, and members of the microbiome utilize bile acids and their conjugates resulting in agonism of FXR in intestine and liver resulting in a smaller, unconjugated hydrophobic bile Acid pool.
Journal ArticleDOI
Altered profile of human gut microbiome is associated with cirrhosis and its complications
Jasmohan S. Bajaj,Douglas M. Heuman,Phillip B. Hylemon,Arun J. Sanyal,Melanie B. White,Pamela Monteith,Nicole A. Noble,Ariel Unser,Kalyani Daita,Andmorgan R. Fisher,Masoumeh Sikaroodi,Patrick M. Gillevet +11 more
TL;DR: In the longitudinal matched-cohort, microbiota were significantly different between infected/uninfected cirrhotics at baseline and a low CDR was associated with death and organ failures within 30days, indicating progressive changes in the gut microbiome accompany cirrhosis and become more severe in the setting of decompensation.
Journal ArticleDOI
Interactions between the intestinal microbiome and liver diseases.
Bernd Schnabl,David A. Brenner +1 more
TL;DR: The contribution of the intestinal microbiome to liver disease goes beyond simple translocation of bacterial products that promote hepatic injury and inflammation and is reviewed to ensure that microbial metabolites produced in a dysbiotic intestinal environment and host factors are equally important in the pathogenesis of liver disease.
Journal ArticleDOI
The gut-liver axis in liver disease: Pathophysiological basis for therapy.
TL;DR: The identification of the elements of the gut-liver axis primarily damaged in each chronic liver disease offers possibilities to intervention.
References
More filters
Journal ArticleDOI
Bile salt biotransformations by human intestinal bacteria.
TL;DR: The potential exists for altering the bile acid pool by targeting key enzymes in the 7α/β-dehydroxylation pathway through the development of pharmaceuticals or sequestering bile acids biologically in probiotic bacteria, which may result in their effective removal from the host after excretion.
Journal ArticleDOI
Dietary-fat-induced taurocholic acid promotes pathobiont expansion and colitis in Il10 −/− mice
Suzanne Devkota,Yunwei Wang,Mark W. Musch,Vanessa Leone,Hannah Fehlner-Peach,Anuradha Nadimpalli,Dionysios A. Antonopoulos,Bana Jabri,Eugene B. Chang +8 more
TL;DR: Dietary fats, by promoting changes in host bile acid composition, can markedly alter conditions for gut microbial assemblage, resulting in dysbiosis that can perturb immune homeostasis, providing a plausible mechanistic basis by which Western-type diets high in certain saturated fats might increase the prevalence of complex immune-mediated diseases like inflammatory bowel disease in genetically susceptible hosts.
Journal ArticleDOI
Dietary fat-induced taurocholic acid production promotes pathobiont and colitis in IL-10−/− mice
Suzanne Devkota,Yunwei Wang,Vanessa Leone,Mark W. Musch,Anuradha Nadimpalli,Dion Antonopoulos,Bana Jabri,Eugene B. Chang +7 more
Journal ArticleDOI
Rifaximin treatment in hepatic encephalopathy.
Nathan M. Bass,Kevin D. Mullen,Arun J. Sanyal,Fred Poordad,Guy W. Neff,Carroll B. Leevy,Samuel H. Sigal,Muhammad Y. Sheikh,Kimberly Beavers,Todd Frederick,Lewis W. Teperman,Donald J. Hillebrand,Shirley Huang,Kunal Merchant,Audrey L. Shaw,Enoch Bortey,William P. Forbes +16 more
TL;DR: Over a 6-month period, treatment with rifaximin maintained remission from hepatic encephalopathy more effectively than did placebo, and also significantly reduced the risk of hospitalization involving hepaticEncephalopathy.
Journal ArticleDOI
Characterization of fecal microbial communities in patients with liver cirrhosis
Yanfei Chen,Fengling Yang,Haifeng Lu,Baohong Wang,Yunbo Chen,Dajiang Lei,Yuezhu Wang,Baoli Zhu,Lanjuan Li +8 more
TL;DR: Fecal microbial communities are distinct in patients with cirrhosis compared with healthy individuals, and the prevalence of potentially pathogenic bacteria, such as Enterobacteriaceae and Streptococcaceae, with the reduction of beneficial populations such as Lachnospiraceae in Patients with Cirrhosis may affect prognosis.
Related Papers (5)
Alterations of the human gut microbiome in liver cirrhosis
Nan Qin,Fengling Yang,Ang Li,Edi Prifti,Yanfei Chen,Li Shao,Jing Guo,Jian Yao,Lingjiao Wu,Jiawei Zhou,Ni Shujun,Lin Liu,Nicolas Pons,Jean-Michel Batto,Sean Kennedy,Pierre Leonard,Chunhui Yuan,Wenchao Ding,Yuanting Chen,Xinjun Hu,Beiwen Zheng,Guirong Qian,Wei Xu,S. Dusko Ehrlich,Shu-Sen Zheng,Lanjuan Li +25 more